Agios Pharmaceuticals Inc (NAS:AGIO)
$ 58.945 -0.075 (-0.13%) Market Cap: 3.36 Bil Enterprise Value: 2.42 Bil PE Ratio: 5.19 PB Ratio: 2.07 GF Score: 37/100

Agios Pharmaceuticals Inc to Discuss the FDA Approval of PYRUKYND Call Transcript

Feb 18, 2022 / 12:00PM GMT
Release Date Price: $29.42 (-0.14%)
Holly Manning
Agios Pharmaceuticals, Inc. - Senior Director of IR

All right. It's 7:00, so let's go ahead and get started. Thank you, everyone, for joining our approval event today. We will -- we have some prepared remarks. We'll go through our label and commercial plans. And then at the end, we'll have time for Q&A. (Operator Instructions) So Jackie, I will turn it over to you.

Jacqualyn A. Fouse
Agios Pharmaceuticals, Inc. - CEO & Director

Thank you, Holly. Good early morning, everyone, and thank you for joining us early this morning. It's a very exciting time for us at Agios today as we got our first genetically defined disease indication drug approval yesterday, and we're just thrilled with that and look forward to speaking with you about it today.

Just as a reminder, less exciting, but necessary, this presentation will include forward-looking statements. Before we get started with the specifics of today's -- or yesterday, actually, announcement I want to start with one of the key ways that we differentiate ourselves at Agios with what

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot